IKT

Business Context and Reporting Period

Company: Inhibikase Therapeutics, Inc. (IKT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib mesylate, for the treatment of Pulmonary Arterial Hypertension (PAH). The company is currently enrolling patients in its pivotal global Phase 3 clinical study, IMPROVE-PAH, across 43 activated sites in 26 countries.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 52.5% to $36.0 million for the six months ended June 30, 2026, compared to $23.6 million in the prior year period. This was driven primarily by increased R&D spending for the Phase 3 trial.
• R&D Expenses: Increased by 53.5% to $24.2 million. The prior year period included a one-time non-cash charge of $7.4 million for acquired in-process research and development (IPR&D) from the CorHepta acquisition, which did not recur. Excluding this, the increase is attributed to PAH clinical trial costs.
• SG&A Expenses: Increased by 34.6% to $15.0 million, primarily due to a $3.5 million increase in stock-based compensation expense.
• Contingent Consideration: The change in fair value of contingent consideration decreased by 75.5% to $0.4 million (gain) compared to $1.5 million (gain) in the prior period, as the service milestone for the CorHepta acquisition was satisfied and settled in February 2026.
• Liquidity Position: Cash and cash equivalents decreased from $139.2 million at year-end 2025 to $31.2 million at June 30, 2026, while marketable securities increased significantly to $127.8 million due to net purchases of $86.4 million.

Guidance, Outlook, and Risks

• Clinical Progress: The IMPROVE-PAH Phase 3 study is actively enrolling. In May 2026, pre-clinical and Phase 1 data were presented demonstrating a potentially improved gastrointestinal side-effect profile for IKT-001 compared to imatinib.
• Regulatory Milestone: In July 2026 (subsequent to period end), the FDA granted Orphan Drug Designation (ODD) for IKT-001 for PAH, providing potential tax credits, user fee exemptions, and seven years of market exclusivity upon approval.
• Liquidity Outlook: Management estimates that existing cash, cash equivalents, and marketable securities ($159.0 million as of June 30, 2026) are sufficient to fund operations for at least the next twelve months. This estimate assumes the full and timely exercise of outstanding Series A and B Warrants.
• Capital Raising: In July 2026, the company sold 25.3 million shares via its ATM facility for gross proceeds of $50.5 million. The company anticipates needing substantial additional funding to complete development and commercialization.
• Key Risks:
  • Manufacturing Supply Chain: Reliance on STA Pharmaceutical Hong Kong Limited (a subsidiary of WuXi AppTec), which has been designated as a "biotechnology company of concern" under the BIOSECURE Act. While a preliminary injunction was granted in August 2026, future restrictions could force a costly and time-consuming transition to alternative manufacturers.
  • Regulatory & Clinical: Risks associated with patient enrollment, trial outcomes, and obtaining regulatory approval.
  • Capital Availability: Inability to raise additional capital on favorable terms could delay or discontinue development.

Investor Verification Checklist

• Warrant Exercise Status: Verify the likelihood and timing of the exercise of Series A-1 and Series B-1 warrants, which are critical to the company's liquidity runway estimates.
• Manufacturing Contingency: Assess the company's specific contingency plans and costs associated with the potential loss of WuXi AppTec/STA Pharmaceutical as a manufacturing partner due to U.S. regulatory restrictions.
• Phase 3 Enrollment Rates: Monitor the pace of patient enrollment in the IMPROVE-PAH trial to ensure it aligns with the projected cash burn rate.
• ATM Facility Usage: Track future sales under the Open Market Sale Agreement to gauge dilution and capital raising efficiency.
• Contractual Commitments: Review the $106.6 million in remaining CRO commitments and $9.8 million in CMO commitments to understand future cash outflow obligations.